The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet ...
Scott Plesha, CEO, stated that Pelthos made “great progress” in three key areas: ZELSUVMI’s “substantial demand-generated revenue growth” following its Q3 launch, the acquisition of two FDA-approved ...
(RTTNews) - Ligand Pharmaceuticals Inc. (LGND) and Pelthos Therapeutics Inc. announced Wednesday the closing of the previously announced merger agreement with Channel Therapeutics Corp. (CHRO), ...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) ...
Zelsuvmi is expected to be available in the second half of 2024. The Food and Drug Administration (FDA) has approved Zelsuvmi ™ (berdazimer topical gel) for the treatment of molluscum contagiosum in ...
Pelthos Therapeutics is looking to protective mothers to raise awareness about the treatment of an infection that causes sores. The company, which until recently was part of Ligand Pharmaceuticals, ...
Ligand Pharmaceuticals’ topical skin infection gel Zelsuvmi is changing hands again—sort of. After Ligand last year created Pelthos Therapeutics to support the launch of Zelsuvmi, Pelthos is now ...
JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results